pembrolizumab
merck
['pembro']
thomas marron, md, phd, will present today at 6:50 pm:
flt3l-primed in situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and er/pr+ breast cancer
#sitc2022 